Jade Biosciences, Inc. (JBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.03B
Last updated: Nov 17, 2026 at 11:06 AM ET
Jade Biosciences, Inc. (JBIO) Competitors
The companies most similar to Jade Biosciences are Climb Bio (CLYM), MoonLake Immunotherapeutics (MLTX) and Syndax Pharmaceuticals (SNDX). By market cap, Jade Biosciences ranks 7th of the 13 companies on this page; Zenas BioPharma, Inc. Common Stock (ZBIO) is the largest at $1.90B.
Peer Comparison
JBIO's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Jade Biosciences (JBIO) | $1.03B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Climb Bio Inc (CLYM) | $608.53M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| MoonLake Immunotherapeutics (MLTX) | $1.06B | N/A | N/A | 0.0% | -54.6% | 0.0% | 0.00% |
| Syndax Pharmaceuticals Inc (SNDX) | $850.77M | N/A | 2.8x | -72.3% | -65.0% | 81.6% | 0.00% |
| Solid Biosciences LLC (SLDB) | $763.42M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Theravance Biopharma Inc (TBPH) | $884.18M | 95.1x | 8.4x | 51.6% | N/A | -20.9% | 0.00% |
| Intellia Therapeutics Inc (NTLA) | $1.36B | N/A | 26.1x | 0.0% | -50.0% | -48.0% | 0.00% |
| Immix Biopharma Inc (IMMX) | $657.09M | N/A | N/A | 0.0% | -14.9% | 0.0% | 0.00% |
| Vir Biotechnology Inc (VIR) | $1.71B | N/A | 5.4x | -61.0% | N/A | 19582.0% | 0.00% |
| Inhibrx Biosciences, Inc. (INBX) | $1.23B | N/A | 610.4x | 0.0% | -66.0% | -100.0% | 0.00% |
| Immatics NV (IMTX) | $972.99M | N/A | 17.7x | 0.0% | N/A | 33.5% | 0.00% |
| Zenas BioPharma, Inc. Common Stock (ZBIO) | $1.90B | N/A | 168.0x | 0.0% | -104.3% | -100.0% | 0.00% |
| Vor Biopharma Inc (VOR) | $1.19B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $1.02B | 95.1x | 17.7x | 0.0% | -59.8% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Jade Biosciences, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Climb Bio Inc (CLYM) | Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. | CLYM competitors |
| MoonLake Immunotherapeutics (MLTX) | MoonLake Immunotherapeutics is an innovative biotechnology firm dedicated to advancing therapies for chronic inflammatory diseases through its proprietary drug... | MLTX competitors |
| Syndax Pharmaceuticals Inc (SNDX) | Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. | SNDX competitors |
| Solid Biosciences LLC (SLDB) | Solid Biosciences Inc., a life sciences company, is dedicated to developing therapies for Duchenne muscular dystrophy (DMD) in the United States. | SLDB competitors |
| Theravance Biopharma Inc (TBPH) | Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe... | |
| Intellia Therapeutics Inc (NTLA) | Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts. | NTLA competitors |
| Immix Biopharma Inc (IMMX) | Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology... | IMMX competitors |
| Vir Biotechnology Inc (VIR) | Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. | VIR competitors |
| Inhibrx Biosciences, Inc. (INBX) | Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. | INBX competitors |
| Immatics NV (IMTX) | Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies... | IMTX competitors |
| Zenas BioPharma, Inc. Common Stock (ZBIO) | Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based... | ZBIO competitors |
| Vor Biopharma Inc (VOR) | Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. | VOR competitors |
Frequently Asked Questions About JBIO
Who are Jade Biosciences' main competitors?
The companies most similar to Jade Biosciences include Climb Bio (CLYM), MoonLake Immunotherapeutics (MLTX), Syndax Pharmaceuticals (SNDX), Solid Biosciences LLC (SLDB) and Theravance Biopharma (TBPH), listed from the closest match.
Who is Jade Biosciences' biggest competitor?
Zenas BioPharma, Inc. Common Stock (ZBIO) is the largest of the similar companies at $1.90B; Climb Bio (CLYM) is the closest match by business profile, size, sector and industry.
How does JBIO stock compare with its competitors?
JBIO's net margin is 0.0% against a peer median of 0.0%.
Which of Jade Biosciences' competitors pays a higher dividend?
Jade Biosciences pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Jade Biosciences bigger than its competitors?
No. Jade Biosciences is 7th by market cap among the 13 companies on this page; the largest is Zenas BioPharma, Inc. Common Stock (ZBIO) at $1.90B.
JBIO pages: Overview, Earnings, Forecast, Financials, Competitors